Published in:

Open Access 02-04-2025 | Coronary Heart Disease | Review

The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention

Authors: Chukwuemezie Kamanu, Dean G. Karalis

Published in: Current Atherosclerosis Reports | Issue 1/2025

Abstract

Purpose of Review

Atherosclerotic cardiovascular disease (ASCVD) remains a leading global health challenge, with low-density lipoprotein (LDL) cholesterol a pivotal risk factor. While statins are cornerstone therapy for lowering LDL cholesterol, many high-risk primary prevention patients are unable to tolerate statin therapy and do not achieve their guideline directed LDL cholesterol goal. For these patients, non-statin therapies offer complementary and alternative approaches to LDL cholesterol reduction.

Recent Findings

Recent advancements in non-statin therapies have expanded the options available to clinicians to lower LDL cholesterol in high-risk primary prevention patients. Yet these medications are often under-utilized in clinical practice.

Summary

Observational studies, Mendelian randomization studies, and randomized clinical trials support the role of non-statin LDL cholesterol lowering therapies in the primary prevention of ASCVD. This review summarizes the evidence supporting their use for the primary prevention of ASCVD and offers practical suggestions as to how clinicians can integrate these medications into their clinical practice.

Martin SS, Aday AW, Almarzooq ZI, et al. Circulation. 2024;149(8):e347–913. https://doi.org/10.1161/CIR.0000000000001209. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.

Woodruff RC, Tong X, Khan SS, et al. Trends in cardiovascular disease mortality rates and excess deaths, 2010–2022. Am J Prev Med. 2024;66(4):582–9. https://doi.org/10.1016/j.amepre.2023.11.009.CrossRefPubMed

Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of Statin therapy. Lancet. 2016;388(10059):2532–61. https://doi.org/10.1016/s0140-6736(16)31357-5.CrossRefPubMed

Grundy SM, Stone NJ, Bailey AL, NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25). https://doi.org/10.1161/cir.0000000000000625.

Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on Statin intolerance: a new definition and key considerations for ASCVD risk reduction in the Statin intolerant patient. J Clin Lipidol. 2022;16(4):361–75. https://doi.org/10.1016/j.jacl.2022.05.068.CrossRefPubMed

Nielsen SF, Nordestgaard BG. Negative Statin-related news stories decrease Statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37(11):908–16. https://doi.org/10.1093/eurheartj/ehv641.CrossRefPubMed

Beshir SA, Hussain N, Elnor AA, Said ASA. Umbrella review on Non-Statin Lipid-Lowering therapy. J Cardiovasc Pharmacol Therap. 2021;26(5):437–52. https://doi.org/10.1177/10742484211002943.

Saeed A, Zhu J, Thoma F, et al. Cardiovascular disease Risk-Based Statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network. Circ Cardiovasc Qual Outcomes. 2021;14(9):e007485. https://doi.org/10.1161/circoutcomes.120.007485.CrossRefPubMed

Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366–418. https://doi.org/10.1016/j.jacc.2022.07.006. The newest recommendations from the American College of Cardiology for selecting non-statin therapies in high risk patients on a maximally tolerated statin who need additional LDL cholesterol lowering.

10.

• Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484. Newest European recommendations for adding non-statin therapies for high risk patients.

11.

Toth P, Phan, Dayspring T. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012. https://doi.org/10.2147/vhrm.S33664.CrossRefPubMedPubMedCentral

12.

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.

13.

Baigent C, Landray MJ, Reith C, et al. The effects of Lowering LDL cholesterol with Simvastatin plus Ezetimibe in patients with chronic kidney disease (Study of heart and renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377(9784):2181–92. https://doi.org/10.1016/s0140-6736(11)60739-3.

14.

Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75). Circulation. 2019;140(12):992–1003. https://doi.org/10.1161/circulationaha.118.039415.CrossRefPubMed

15.

Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273–93. https://doi.org/10.1146/annurev-pharmtox-011613-140025.CrossRefPubMed

16.

Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid Lowering therapy. World J Cardiol. 2017;9(2). https://doi.org/10.4330/wjc.v9.i2.76.

17.

Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of Evolocumab. J Am Coll Cardiol. 2014;63(23):2531–40. https://doi.org/10.1016/j.jacc.2014.03.018.CrossRefPubMed

18.

Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of Bococizumab in High-Risk patients. N Engl J Med. 2017;376(16):1527–39. https://doi.org/10.1056/NEJMoa1701488.CrossRefPubMed

19.

Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024;21(7):487–97. https://doi.org/10.1038/s41569-023-00979-8.CrossRefPubMed

20.

Bohula EA, Marston NA, Ruzza A, et al. Rationale and design of the effect of Evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. Am Heart J. 2024;269:179–90. https://doi.org/10.1016/j.ahj.2023.12.004.CrossRefPubMed

21.

Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51. https://doi.org/10.1056/NEJMoa1609243.CrossRefPubMed

22.

Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047–57. https://doi.org/10.1093/eurheartj/ehac615.CrossRefPubMedPubMedCentral

23.

Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. https://doi.org/10.1056/NEJMoa1912387.CrossRefPubMed

24.

Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran. Journal of the American Heart Association. 2024; 13(6):e032031. https://doi.org/10.1161/JAHA.123.032031.

25.

HPS-4/TIMI 65/ORION-4. A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease. In. Edited by The TSG, Novartis P; 2018.

26.

Randomized A. Double-blind, Placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in High-risk primary prevention patients (VICTORION-1 PREVENT). In.; 2023.

27.

Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a united States lipid clinic. J Clin Lipidol. 2023;17(1):73–7. https://doi.org/10.1016/j.jacl.2022.10.009.CrossRefPubMed

28.

Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. https://doi.org/10.1056/NEJMoa1803917.CrossRefPubMed

29.

• Nissen SE, Lincoff AM, Brennan D et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine. 2023; 388(15):1353–1364. https://doi.org/10.1056/NEJMoa2215024. This randomized trial evaluated the efficacy and safety of bempedoic acid compared to placebo in statin-intolerant patients with or at high risk for cardiovascular disease. The study demonstrated that bempedoic acid significantly reduced LDL cholesterol levels and lowered the risk of cardiovascular events.

30.

• Nissen SE, Menon V, Nicholls SJ et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023; 330(2):131–140. https://doi.org/10.1001/jama.2023.9696. A subgroup analysis of the original study, demonstrating that in high risk primary prevention population, bempedoic acid therapy was associated with a significant reduction in major adverse cardiovascular events.

31.

Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated Statins on Low-Density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585.CrossRefPubMedPubMedCentral

32.

Lincoff AM, Ray KK, Sasiela WJ, et al. Comparative cardiovascular benefits of bempedoic acid and Statin drugs. J Am Coll Cardiol. 2024;84(2):152–62. https://doi.org/10.1016/j.jacc.2024.04.048.CrossRefPubMed

33.

Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus Ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated Statin therapy. Eur J Prev Cardiol. 2020;27(6):593–603. https://doi.org/10.1177/2047487319864671.CrossRefPubMed

34.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRef

35.

The Lipid Research Clinics Coronary Primary. Prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–64. https://doi.org/10.1001/jama.1984.03340270029025.CrossRef

36.

Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm– 2020 executive summary. Endocr Pract. 2020;26(10):1196–224. https://doi.org/10.4158/cs-2020-0490.CrossRefPubMed

37.

Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Circulation. 2001;103(23):2828–33. https://doi.org/10.1161/01.cir.103.23.2828.CrossRefPubMed

38.

Frick M.H, Elo O, Haapa K, et al. Helsinki heart study: Primary-Prevention trial with gemfibrozil in Middle-Aged men with dyslipidemia. N Engl J Med. 1987;317(20):1237–45. https://doi.org/10.1056/NEJM198711123172001.

39.

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563–74. https://doi.org/10.1056/NEJMoa1001282.

40.

Keech A, Simes RJ, Barter P, et al. Effects of long-term Fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366(9500):1849–61. https://doi.org/10.1016/s0140-6736(05)67667-2.

41.

Pradhan AD, Glynn RJ, Fruchart J-C, et al. Triglyceride Lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923–34. https://doi.org/10.1056/NEJMoa2210645.

42.

Ito MK. A comparative overview of prescription Omega-3 fatty acid products. P T. 2015;40(12):826–57.PubMedPubMedCentral

43.

Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American heart association/american college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9–119. https://doi.org/10.1161/CIR.0000000000001168.

44.

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent Ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.

45.

Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-Dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–80. https://doi.org/10.1001/jama.2020.22258.CrossRefPubMedPubMedCentral

46.

McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164(7):697–705. https://doi.org/10.1001/archinte.164.7.697.CrossRefPubMed

47.

Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440–6. https://doi.org/10.1016/j.jacc.2012.10.030.CrossRefPubMed

48.

Safarova MS, Moriarty PM, Kullo IJ, Ballantyne CM, Gianos E. Bempedoic acid falls in line. J Am Coll Cardiol. 2024;84(2):163–4. https://doi.org/10.1016/j.jacc.2024.05.027.CrossRefPubMed

49.

Bradley CK, Wang TY, Li S, et al. Patient-Reported reasons for declining or discontinuing Statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8(7):e011765. https://doi.org/10.1161/jaha.118.011765.CrossRefPubMedPubMedCentral

Title: The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention
Authors: Chukwuemezie Kamanu
Dean G. Karalis
Publication date: 02-04-2025
Publisher: Springer US
Keywords: Coronary Heart Disease
Acute Coronary Syndrome
Ezetimibe
PCSK9 Inhibitor
Evolocumab
Statins
Hypercholesterolemia
Published in: Current Atherosclerosis Reports / Issue 1/2025
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-025-01283-1

The Role of Iron in Atherosclerosis and its Association with Related Diseases

Arterial Occlusive Disease
Review

Impact of Sex Differences on Lipids and Statin Utilization

Statins
Review

How do built environments impact CVD?

Circulatory Disease
Review

Exposomic Determinants of Atherosclerosis: Recent Evidence

Arterial Occlusive Disease
Review

Novel Therapeutics for Familial Chylomicronemia Syndrome

Open Access
Hypertriglyceridemia
Review

Role of Aspirin in Reducing Risk for Atherosclerotic Cardiovascular Disease in Individuals with Elevated Lipoprotein(a)

Coronary Heart Disease
Review

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention

Abstract

Purpose of Review

Recent Findings

Summary

Other articles of this Issue 1/2025

The Role of Iron in Atherosclerosis and its Association with Related Diseases

Impact of Sex Differences on Lipids and Statin Utilization

How do built environments impact CVD?

Exposomic Determinants of Atherosclerosis: Recent Evidence

Novel Therapeutics for Familial Chylomicronemia Syndrome

Role of Aspirin in Reducing Risk for Atherosclerotic Cardiovascular Disease in Individuals with Elevated Lipoprotein(a)

Keynote series | Spotlight on menopause

A quick guide to ECGs

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content